强化降压治疗的靶器官保护效应及其临床预后价值
Target organ protection and clinical prognostic value of intensive blood pressure lowering therapy
高血压是全球范围内最常见的心血管疾病之一,长期血压控制不佳可导致心、脑、肾、眼等靶器官结构与功能损伤。早期安全实现血压的有效控制,已成为全球医疗体系亟待解决的重大任务。然而,目前关于早期强化降压的获益及安全性平衡、人群适用性及临床应用仍存在争议。本文系统综述强化降压治疗的发展历程、国际指南目标差异,以及特殊人群的血压控制目标与循证证据。同时阐述强化降压对心脏、脑血管及肾脏靶器官的保护机制与临床获益。现有证据表明,在患者耐受的前提下,强化降压可带来更多获益。但降压方式需遵循个体化原则,小剂量起步、缓慢达标。未来应进一步探索精准化降压方案,加强长期安全性与成本效益研究,推动高血压治疗从“适度控制”向“精准强化”转变。
Hypertension is one of the most prevalent cardiovascular diseases globally. Prolonged inadequate blood pressure control can lead to structural and functional damage in target organs, including the heart, brain, kidneys and eyes. Achieving effective and safe blood pressure control at an early stage has become a critical priority for healthcare systems worldwide. However, controversies persist regarding the balance between the benefits and safety of early intensive blood pressure lowering, its applicability across diverse populations, and its clinical implementation. This review systematically summarizes the development of intensive blood pressure lowering therapy, variations in target blood pressure values among international guidelines, and evidence-based recommendations for blood pressure control targets for special populations. It also elucidates the underlying protective mechanisms and clinical benefits of intensive blood pressure lowering on target organs. Current evidence indicates that intensive blood pressure lowering can confer additional benefits in patients who tolerate it well. However, treatment strategies should adhere to individualized principles, including low-dose initiation and gradual target achievement. Future research should focus on precision blood pressure lowering strategies, as well as long-term safety and cost-effectiveness, to facilitate the transition of hypertension management from "moderate control" to "precision intensification".
| [1] |
|
| [2] |
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. J Am Coll Cardiol, 2025, 86(22): 2167-2243. DOI: 10.1016/j.jacc.2025.08.015. |
| [3] |
国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告 2024 概要[J]. 中国循环杂志, 2025, 40(6): 521-559. DOI: 10.3969/j.issn.1000-3614.2025.06.001. |
| [4] |
|
| [5] |
McEvoy JW, McCarthy CP, Bruno RM, |
| [6] |
Writing Committee Members, |
| [7] |
中国高血压防治指南修订委员会, 高血压联盟, 中国医疗保健国际交流促进会高血压分会, |
| [8] |
Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular event[J]. Prog Cardiovasc Dis, 2016, 59(3): 262-281. DOI: 10.1016/j.pcad.2016.04.001. |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
中华医学会糖尿病学分会糖尿病与肥胖学组, 中国高血压联盟, 祝之明, |
| [17] |
中国老年医学学会高血压分会, 北京高血压防治协会, 国家老年疾病临床医学研究中心 (中国人民解放军总医院, 首都医科大学宣武医院). 中国老年高血压管理指南 2023[J]. 中华高血压杂志, 2023, 31(6): 508-538. DOI: 10.16439/j.issn.1673-7245.2023.06.003. |
| [18] |
王增武, 王圣, 冯彩霞, |
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
Rahimi K, Bidel Z, Nazarzadeh M, |
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
公绪合, 丁彦春, 张鹏强. 降压治疗中的 J 形曲线[J]. 中华高血压杂志, 2011, 19(8): 744-749. DOI: 10.16439/j.cnki.1673-7245.2011.08.010. |
| [35] |
|
大连市登峰计划科研项目(2021024)
/
| 〈 |
|
〉 |